The new 25,000 sq. ft., FDA-registered facility, located within the company’s existing Web Boston location, will allow the company to provide manufacturing solutions for companies who market LFI tests, the Marlborough, Mass.-based company said.
“Our goal with the opening of this facility, Web Industries will become the only non-competing contract manufacturing organization in the U.S. to offer commercial scale bio-chemistry laboratory capabilities – combined with automated reel-to-reel test strip manufacturing, lateral flow rapid test device assembly, private labeling, packaging and distribution for the leading testing device brands around the world,” chief sales and marketing officer Blake Batley said at the opening of the facility.
The center was purpose-built for automated reel-to-reel medical device production, featuring a climate controlled in-house biochemistry lab, reagent deposition lab , LFI strip manufacturing equipment, device assembly and packaging stations.
Web Industries said the opening makes it the only U.S.-based non-competing medical CMO to offer automated reel-to-reel LFI strip manufacturing, device assembly and packing services at commercial-size volumes.
“By being the 1st company to provide the market with these services, we have a unique opportunity to become the world’s leading FDA-registered contract manufacturer for advanced LFI devices,” Bately said.
The additional facilities will allow for the addition of 10 jobs this year, Web Industries said, looking to add another 30 by 2020, with eventual production capabilities for up to 20 million devices annually.
“We’re excited to bring these unique production capabilities and capacities to the LFI device market. Recent medical and environmental issues have demonstrated the strong need for easily deployable rapid tests, and our company’s long history of success in the IVD test, diagnostic strip, and medical consumable markets position us as the manufacturing partner LFI marketers can rely on to help safeguard personal and public health,” president Mark Pihl said in a press release.